• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Syngene International Ltd.
    25 Jul 2025
    609.45
    -4.31%
    Syngene International CEO Confident Of Maintaining Mid-Teens Revenue Growth In FY26 After Strong Q1 Results
    Syngene International CEO Confident Of Maintaining Mid-Teens Revenue Growth In FY26 After Strong Q1 Results
    NDTV Profit
    Syngene International has made a robust start to the financial year 2025-26, with a strong growth in revenue from operations and the net profit in the first quarter.
    Copy LinkShare onShare on Share on Share on
    Syngene International Ltd. is trading below all available SMAs
    Pilot wins, biologics ramp-up drive Syngene's Q1; PAT growth to moderate, says Peter Bains
    Business Line | 24 Jul 2025
    logo
    Dr. Reddy's Laboratories Ltd.
    24 Jul 2025
    1253.10
    -1.73%
    Q1 miss for Dr Reddy's, but analysts remain hopeful for future prospects
    Business Standard
    Despite missing Q1 expectations, Dr Reddy's continues to see growth in key markets like Europe and India, while managing costs to offset challenges in the US
    Copy LinkShare onShare on Share on Share on
    Dr. Reddy's Laboratories Ltd. is trading below its 30 day SMA of 1280.7
    logo
    Lupin Ltd.
    24 Jul 2025
    US FDA Approval
    1919.80
    -2.23%
    Lupin gets USFDA nod for generic diabetes drugs
    Business Line
    The company received approval from the USFDA for its abbreviated new drug applications for Liraglutide Injection single-patient-use prefilled pens and glucagon for injection vials, the drug maker said in a statement
    Copy LinkShare onShare on Share on Share on
    Lupin Ltd. has an average target of 2326.00 from 8 brokers.
    logo
    Senores Pharmaceuticals Ltd.
    24 Jul 2025
    673.60
    -3.82%
    Senores Pharma hits all time high on posting Q1 results; PAT up 95% YoY
    Business Standard
    Senores Pharmaceuticals shares touched an all-time high in trade, gaining 15.6 per cent in trade on BSE after posting Q1 results
    Copy LinkShare onShare on Share on Share on
    Senores Pharmaceuticals Ltd.'s price crossed below 50Day SMA today
    logo
    Dr. Reddy's Laboratories Ltd.
    24 Jul 2025
    1253.10
    -1.73%
    Dr. Reddy's Shares Spike After Morgan Stanley, BofA Raises Price Target Post Q1 Results
    Dr. Reddy's Shares Spike After Morgan Stanley, BofA Raises Price Target Post Q1 Results
    NDTV Profit
    The company posted a consolidated net profit of Rs 1,418 crore for the AprilJune period, up just 1.8% year-on-year and below the Rs 1,514 crore consensus estimate.
    Copy LinkShare onShare on Share on Share on
    Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.
    Dr. Reddy's Q1 Results Review: Systematix Maintains 'Hold' Rating On Weak U.S. Performance
    NDTV Profit | 24 Jul 2025 9 more
    Dr Reddy's Laboratories Q1 print misses target; brokerages split on outlook
    Business Standard | 24 Jul 2025
    Dr. Reddy's Q1 Review: Brokerage Split On Margin Recovery What's The Takeaway?
    NDTV Profit | 24 Jul 2025
    Dr Reddy's Q1 result: Net profit up 2%, revenue hits record 8,545 crore
    Business Standard | 23 Jul 2025
    At 1,409 crore, Dr Reddy's Q1 FY26 net profit up 1%
    Business Line | 23 Jul 2025
    Dr Reddy's Q1 profit up 1% to 1,410 crore, revenue rises to 8,545 cr
    Business Standard | 23 Jul 2025
    Dr Reddy's Laboratories Q1 Results: Profit Up 1.8%, Misses Estimates
    NDTV Profit | 23 Jul 2025
    Dr Reddy's reports 1% rise in Q1 profit to 1,409 cr; revenue up 11%
    Business Line | 23 Jul 2025
    Dr Reddy's Q1 FY26: Double digit growth in topline, pressure on margins likely
    Business Line | 23 Jul 2025
    Dr Reddy's Q1 Results Preview: Analysts Outlook Mixed, See Double-Digit Growth
    NDTV Profit | 22 Jul 2025
    logo
    Natco Pharma Ltd.
    24 Jul 2025
    820.75
    -2.56%
    Natco Pharma to acquire 35.75% stake in South Africa's Adcock Ingram for 1,970 cr
    Business Line
    Natco said the strategic investment aims to expand its geographic presence in South Africa, marking a significant global step for the Indian pharmaceutical company.
    Copy LinkShare onShare on Share on Share on
    Number of MF schemes decreased from 54 to 47 in Jun 2025 qtr
    Natco Pharma to acquire 35.75% stake in Adcock Ingram for 2,000 cr
    Business Standard | 23 Jul 2025
    logo
    Syngene International Ltd.
    23 Jul 2025
    609.45
    -4.31%
    At 87 crore, Syngene posts 61% growth in profit in Q1
    Business Line
    CFO Deepak Jain noted that the current quarter's PAT includes a tax benefit from the transfer of gratuity funds to the employee gratuity trust.
    Copy LinkShare onShare on Share on Share on
    Syngene International Ltd. is trading below all available SMAs
    Syngene Q1 PAT up 59% to 87 crore, operational revenue rises 11%
    Business Standard | 23 Jul 2025 1 more
    Syngene International Q1 Results: Profit Rises 15%, Margin Expands
    NDTV Profit | 23 Jul 2025
    logo
    Cipla Ltd.
    23 Jul 2025
    1499.40
    -0.68%
    Cipla Q1 preview: Net profit may jump up to 4%, revenue by 8% YoY
    Business Standard
    Cipla is scheduled to announce its April-June quarter earnings for the financial year 2025-26 (Q1FY26) on Friday, July 25, 2025
    Copy LinkShare onShare on Share on Share on
    Cipla Ltd. is trading above its 200 day SMA of 1495.0
    logo
    AstraZeneca Pharma India Ltd.
    22 Jul 2025
    8811.50
    -2.39%
    AstraZeneca unveils $50 bn US investment as pharma tariff threat looms
    Business Standard
    On Monday, AstraZeneca said the expansion supports its ambition to reach $80 billion in annual revenue by 2030, with half coming from the US
    Copy LinkShare onShare on Share on Share on
    AstraZeneca Pharma India Ltd. is trading below its 50 day SMA of 8840.3
    logo
    Blue Jet Healthcare Ltd
    22 Jul 2025
    645.90
    -2.85%
    Blue Jet Healthcare shares drop 10% post Q1 results; details here
    Business Standard
    At 2:30 PM, shares of Blue Jet Healthcare were trading at 906.15, down by 10 per cent on the BSE.
    Copy LinkShare onShare on Share on Share on
    Blue Jet Healthcare Ltd has lost -25.73% in the last 3 Months
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • Jinkushal Industries
    • Chatterbox Technologies
    • Rukmani Devi Garg Agro Impex
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd (RA SEBI Reg No: INH000022507)